MEK/RAF+FAK。Verastem。针对复发性低级别浆液性卵巢癌（LGSOC）。$Verastem(VSTM)$

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib. 

网页链接。